Age-Related Macular Degeneration Market Expected To Grow At 7.7% CAGR Through 2030: What Businesses Need To Know
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Age-Related Macular Degeneration Market Size, Value And Growth Trajectory Through 2030
The age-related macular degeneration market size has experienced significant growth in recent years. It is projected to increase from $10.67 billion in 2025 to $11.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.5%. The historical expansion can be attributed to the global aging population, the rising prevalence of AMD, limited treatment options available in earlier periods, increasing awareness of eye health, and the development of hospital and ophthalmology clinic infrastructure.
The market size for age-related macular degeneration is projected to experience robust expansion over the coming years. This market is anticipated to reach $15.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth throughout the forecast period include the creation of advanced anti-VEGF medications, heightened investment in eye research, the broadening reach of specialized pharmacies and digital pharmacy platforms, a surge in the application of combined treatments, and an uptick in the embrace of customized therapeutic strategies. Significant trends anticipated for the forecast period encompass a greater acceptance of anti-VEGF therapies, an escalating reliance on dietary supplements and visual aids for impaired vision, an increase in photodynamic and laser treatment interventions, the broadening of intravitreal and intravenous delivery methods, and enhanced public knowledge coupled with consistent eye examination initiatives.
Get A Free Sample Report With In-Depth Market Insights:
Age-Related Macular Degeneration Market Growth Factors Behind Sustained Expansion
The age-related macular degeneration (AMD) market is anticipated to expand due to the escalating prevalence of age-related macular degeneration (AMD) going forward. This condition is defined as a progressive ocular disorder affecting the macula, a small section of the retina crucial for central vision. Treatments for age-related macular degeneration (AMD) provide support to patients suffering from retinal disorders by minimizing the severity of their condition. For instance, in February 2023, data shared by Optimaxa, a UK-based laser eye treatment specialist, indicated that age-related macular degeneration (AMD) affected 196 million individuals globally and is projected to reach 288 million by 2040, accounting for 8.7 percent of the world’s population. Consequently, the rising prevalence of age-related macular degeneration (AMD) is a key driver for the age-related macular degeneration (AMD) market.
Age-Related Macular Degeneration Market Segment Landscape And Growth Outlook
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Drugs
3) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
Age-Related Macular Degeneration Market Industry Trends Fueling Future Revenue Growth
Leading firms within the age-related macular degeneration (AMD) market are developing cutting-edge technologies, including recombinant antigen-binding fragments. Recombinant antigen-binding fragments (Fab) are designed proteins originating from antibodies, engineered to specifically attach to target antigens, frequently employed in therapeutic uses to block disease pathways. As an example, in December 2023, Enzene Biosciences, an Indian biotechnology enterprise, introduced ranibizumab, a recombinant monoclonal antibody fragment (Fab) specifically designed to impede vascular endothelial growth factor (VEGF), a crucial protein contributing to the formation of abnormal blood vessels in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). By hindering VEGF, ranibizumab effectively reduces the leakage and growth of these blood vessels, thereby aiding in vision preservation for patients suffering from these retinal conditions. Administered via intravitreal injection, it has achieved broad recognition in clinical settings due to its effectiveness in addressing diverse retinal ailments. The availability of ranibizumab has significantly improved treatment options for individuals struggling with these severe disorders.
Age-Related Macular Degeneration Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the age-related macular degeneration market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Outlook Therapeutics Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.
View The Full Age-Related Macular Degeneration Market Report:
Age-Related Macular Degeneration Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the global age-related macular degeneration market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
